Aortic Stenosis and Cardiac Amyloidosis: A Pragmatic, Streamlined International
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Other
Study Type: Observational
SUMMARY
The dual pathology of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized. Even tough efforts have been undertaken to bring cohorts together, the largest cohort of AS-ATTR to date is \<50 patients. It is the aim of the present international, multi-center registry to collect \ 300 patients with AS-CA creating a big enough cohort to allow 1. thorough characterization of this condition 2. assessment of log-term clinical outcomes of AS-CA 3. assessment of effectiveness of amyloid-specific treatment on top of valve replacement
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with significant AS and a concomitant diagnosis of cardiac amyloidosis who are eligible for inclusion as per local permissions
Locations
Other Locations
Austria
Medical University of Vienna
RECRUITING
Vienna
United Kingdom
University College London
RECRUITING
London
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 300
Treatments
AS-CA without amyloid-specific treatment
Patients with no amyloid-specific treatment
AS-CA with amyloid-specific treatment
Patients receiving newly available amyloid-specific drugs
Related Therapeutic Areas
Sponsors
Collaborators: Université Catholique de Louvain, Medical University of South Carolina, Vilnius University Hospital Santaros Klinikos, Columbia University, Royal Free Hospital NHS Foundation Trust, Wolfson Medical Center, Allina Health System, University of Trieste, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Laval University
Leads: Medical University of Vienna